Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)

v3.19.1
Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-In Capital [Member]
Subscription Receivable [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2017 $ 3,527 $ 4,228,723   $ (3,859,086) $ 373,164
Balance, shares at Dec. 31, 2017 35,272,626        
Recognize the fair value of the license acquired from CoNCERT in exchange for 2,090,301 common shares of Processa held by Promet 8,000,000   8,000,000
Net loss   (1,096,798) (1,096,798)
Balance at Mar. 31, 2018 $ 3,527 12,228,723   (4,955,884) 7,276,366
Balance, shares at Mar. 31, 2018 35,272,626        
Balance at Dec. 31, 2018 $ 3,867 19,121,285 $ (1,800,000) (7,624,134) 9,701,018
Balance, shares at Dec. 31, 2018 38,674,265          
Stock-based compensation 58,559 58,559
Payments made directly by investor for clinical trial costs 115,000 115,000
Net loss (750,832) (750,832)
Balance at Mar. 31, 2019 $ 3,867 $ 19,179,844 $ (1,685,000) $ (8,374,966) $ 9,123,745
Balance, shares at Mar. 31, 2019 38,674,265